Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- cytarabine liposomal
- Mavenclad (cladribine)
Interactions between your drugs
cladribine cytarabine liposomal
Applies to: Mavenclad (cladribine), cytarabine liposomal
GENERALLY AVOID: The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.
MANAGEMENT: Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.
References (3)
- (2001) "Product Information. Leustatin (cladribine)." Ortho Biotech Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
Drug and food interactions
cladribine food
Applies to: Mavenclad (cladribine)
ADJUST DOSING INTERVAL: Oral cladribine may increase the bioavailability of other drugs, which may increase the risk or severity of adverse reactions. Cladribine tablets may contain hydroxypropyl betadex, which could form a complex with the active ingredients of other drugs, especially agents with low solubility. The clinical relevance of this interaction remains unknown.
MANAGEMENT: Administration of oral cladribine should be separated from any other oral drug by at least 3 hours.
References (3)
- (2001) "Product Information. Leustatin (cladribine)." Ortho Biotech Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Alimta
Alimta is used to treat non-small cell lung cancer and mesothelioma, a form of lung cancer ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Arranon
Arranon is used to treat T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma ...
Clolar
Clolar is a cancer medicine that is used to treat acute lymphoblastic leukemia (a type of blood ...
Dacogen
Dacogen (decitabine) is used to treat myelodysplastic syndromes (certain types of blood or bone ...
Folotyn
Folotyn is used to treat T-cell lymphoma that has spread throughout the body. Learn about side ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.